3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
23
Neutropenia
22
Neoplasms
7
Chemotherapy-induced Neutropenia
7
Lymphoma, Non-Hodgkin
6
Ovarian Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Triple Negative Breast Neoplasms
3
Lymphoma
3
Fever
3
Febrile Neutropenia
3
Colorectal Neoplasms
3
Rectal Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Hodgkin Disease
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Previously Treated Non Small Cell Lung Cancer
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Malignant Solid Tumors
1
Lymphoma, T-Cell, Peripheral
1
Leukemia, Myeloid, Acute
1
Interventions
Carboplatin
71
Etoposide
63
Topotecan
42
Cisplatin
38
pembrolizumab
30
atezolizumab
26
durvalumab
22
Paclitaxel
16
Nivolumab
14
PM 01183
13
rovalpituzumab tesirine
11
Pemetrexed
11
amrubicin
9
Ipilimumab
9
Injections
9
Irinotecan
8
AMG 757
8
trilaciclib
7
etoposide phosphate
6
EC regimen
6
Drug Therapy
6
Docetaxel
6
Bevacizumab
6
tremelimumab
5
MLN 8237
5
Gemcitabine
5
130-nm albumin-bound paclitaxel
5
olaparib
4
chiauranib
4
budigalimab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Small Cell Lung Carcinoma
×
pegfilgrastim
×
Clear all
NCT01840579
2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1
Completed
57 enrolled
60 charts